Today, the Chairman, President and CEO of Omnicell, Randall Lipps, exercised options of Omnicell (NASDAQ: OMCL) for $1.44M.
In addition to Randall Lipps, 4 other OMCL executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Omnicell’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $183 million and quarterly net profit of $2.72 million. In comparison, last year the company earned revenue of $151 million and had a GAAP net loss of $10.75 million. OMCL’s market cap is $2.04B and the company has a P/E ratio of 60.46. Currently, Omnicell has an average volume of 347.9K.
The insider sentiment on Omnicell has been negative according to 75 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omnicell, Inc. engages in the provision of automation and business analytics software solutions for patient-centric medication and supply management. It operates through Automation and Analytics, and Medication Adherence segments.
